Silence Therapeutics Crescita futura
Criteri Future verificati 2/6
Si prevede che gli utili di Silence Therapeutics diminuiranno a 27.3% all'anno, mentre si prevede che i suoi ricavi annuali cresceranno a 56.2% all'anno. Si prevede che l'EPS crescerà di 20.2% all'anno. Si prevede che il ritorno sul capitale proprio sarà -14.7% in 3 anni.
Informazioni chiave
-27.3%
Tasso di crescita degli utili
20.24%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 25.5% |
| Tasso di crescita dei ricavi | 56.2% |
| Rendimento futuro del capitale proprio | -14.73% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 21 May 2026 |
Aggiornamenti recenti sulla crescita futura
Articolo di analisi • Aug 12
Silence Therapeutics plc (NASDAQ:SLN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
NasdaqGM:SLN 1 Year Share Price vs Fair Value Explore Silence Therapeutics's Fair Values from the Community and select...Articolo di analisi • May 11
Silence Therapeutics plc (NASDAQ:SLN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
The analysts might have been a bit too bullish on Silence Therapeutics plc ( NASDAQ:SLN ), given that the company fell...Articolo di analisi • Aug 18
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
As you might know, Silence Therapeutics plc ( NASDAQ:SLN ) last week released its latest second-quarter, and things did...Recent updates
Articolo di analisi • Feb 05
Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive
To the annoyance of some shareholders, Silence Therapeutics plc ( NASDAQ:SLN ) shares are down a considerable 27% in...Articolo di analisi • Jan 31
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Nov 18
Silence Therapeutics: Divesiran Targets High-Burden PV
Summary Silence Therapeutics is advancing its lead RNAi drug, divesiran, for polycythemia vera, with a fully enrolled Phase 2 trial and results expected in Q3 2026. SLN boasts a strong cash position ($100M+), providing runway through 2028 and enabling continued pipeline development without near-term financing risks. The SANRECO trial's design and patient population position divesiran as a potential adjunctive therapy for high-burden PV patients, focusing on reduced phlebotomy frequency and infrequent dosing. While acknowledging clinical and market risks, I maintain a cautiously optimistic outlook, seeing significant upside if Phase 2 data demonstrate efficacy and safety. Read the full article on Seeking AlphaArticolo di analisi • Oct 19
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Articolo di analisi • Sep 28
Pinning Down Silence Therapeutics plc's (NASDAQ:SLN) P/S Is Difficult Right Now
With a median price-to-sales (or "P/S") ratio of close to 9.9x in the Biotechs industry in the United States, you could...Articolo di analisi • Aug 13
Newsflash: Silence Therapeutics plc (NASDAQ:SLN) Analysts Have Been Trimming Their Revenue Forecasts
NasdaqGM:SLN 1 Year Share Price vs Fair Value Explore Silence Therapeutics's Fair Values from the Community and select...Articolo di analisi • Aug 12
Silence Therapeutics plc (NASDAQ:SLN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
NasdaqGM:SLN 1 Year Share Price vs Fair Value Explore Silence Therapeutics's Fair Values from the Community and select...
Aggiornamento della narrazione • Aug 08
ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline
The upward revision in Silence Therapeutics’ price target reflects significantly improved consensus revenue growth forecasts and a lower future P/E multiple, resulting in an increased fair value estimate from $32.37 to $37.26. What's in the News Silence Therapeutics approved the application of Article 159 of its articles of association, effective from the recent AGM to the next annual general meeting.Articolo di analisi • May 11
Silence Therapeutics plc (NASDAQ:SLN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
The analysts might have been a bit too bullish on Silence Therapeutics plc ( NASDAQ:SLN ), given that the company fell...Articolo di analisi • May 06
Silence Therapeutics plc's (NASDAQ:SLN) Price Is Right But Growth Is Lacking After Shares Rocket 50%
Those holding Silence Therapeutics plc ( NASDAQ:SLN ) shares would be relieved that the share price has rebounded 50...
Nuova narrazione • Apr 01
ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline
The company's strategic partnerships and collaborations could reduce financial risk and enhance revenue growth through shared commercialization and milestone payments.Articolo di analisi • Mar 22
Silence Therapeutics plc (NASDAQ:SLN) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the Silence Therapeutics plc ( NASDAQ:SLN ) share price has dived 29% in the last...Articolo di analisi • Mar 06
These Analysts Think Silence Therapeutics plc's (NASDAQ:SLN) Sales Are Under Threat
Market forces rained on the parade of Silence Therapeutics plc ( NASDAQ:SLN ) shareholders today, when the analysts...Articolo di analisi • Mar 04
We're Keeping An Eye On Silence Therapeutics' (NASDAQ:SLN) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Articolo di analisi • Jan 28
Risks Still Elevated At These Prices As Silence Therapeutics plc (NASDAQ:SLN) Shares Dive 26%
Unfortunately for some shareholders, the Silence Therapeutics plc ( NASDAQ:SLN ) share price has dived 26% in the last...Articolo di analisi • Dec 10
Silence Therapeutics plc (NASDAQ:SLN) May Have Run Too Fast Too Soon With Recent 54% Price Plummet
Silence Therapeutics plc ( NASDAQ:SLN ) shareholders that were waiting for something to happen have been dealt a blow...Articolo di analisi • Oct 04
Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio
You may think that with a price-to-sales (or "P/S") ratio of 38.4x Silence Therapeutics plc ( NASDAQ:SLN ) is a stock...Articolo di analisi • Aug 18
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
As you might know, Silence Therapeutics plc ( NASDAQ:SLN ) last week released its latest second-quarter, and things did...Articolo di analisi • Jun 17
Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit
You may think that with a price-to-sales (or "P/S") ratio of 26.8x Silence Therapeutics plc ( NASDAQ:SLN ) is a stock...Articolo di analisi • May 21
Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. By way of example, Silence...Articolo di analisi • Feb 07
Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues
Silence Therapeutics plc ( NASDAQ:SLN ) shareholders will have a reason to smile today, with the analysts making...Articolo di analisi • Nov 27
Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%
Silence Therapeutics plc ( NASDAQ:SLN ) shares have had a really impressive month, gaining 65% after a shaky period...Seeking Alpha • Sep 08
Silence Therapeutics wins FDA’s fast track status for blood cancer therapy
U.K.-based clinical-stage biotech Silence Therapeutics plc (NASDAQ:SLN) announced Thursday that the FDA granted Fast Track Designation to SLN124 as a treatment for polycythemia vera (PV), a type of blood cancer. SLN124, belonging to a drug class called short interfering ribonucleic acid (siRNA) therapeutics, is set to undergo a Phase 1/2 study in PV this year. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. If certain criteria are met, such programs will also be able to win the Accelerated Approval and Priority Review, enabling them to reach patients sooner. In a clinical trial last year, SLN124 indicated proof of mechanism and was well tolerated among healthy volunteers.Seeking Alpha • Aug 12
Silence Therapeutics prices 5.95M ADSs at $9.50/share
Silence Therapeutics (NASDAQ:SLN) has priced an underwritten offering of 5.95M American Depositary Shares, each representing three ordinary shares, at a price of $9.50/ADS, for aggregate gross proceeds of ~$56.5M. All of the ADSs are being offered by Silence. Offering is expected to close on or about August 16, 2022. Silence intends to use the net proceeds of the offering, together with its existing cash and cash equivalents to fund the advancement of its clinical trials, including its Phase 2 trial of SLN360 in ASCVD and its Phase 1/2 trial of SLN124 in polycythemia vera, as well as expansion of pipeline programs, working capital and general corporate purposes.Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 15 | -139 | -248 | -184 | 5 |
| 12/31/2027 | 6 | -108 | -199 | -132 | 5 |
| 12/31/2026 | 4 | -66 | -76 | -65 | 6 |
| 3/31/2026 | 1 | -75 | -66 | -66 | N/A |
| 12/31/2025 | 1 | -89 | -62 | -62 | N/A |
| 9/30/2025 | 26 | -65 | -73 | -72 | N/A |
| 6/30/2025 | 27 | -79 | -87 | -87 | N/A |
| 3/31/2025 | 28 | -72 | -71 | -71 | N/A |
| 12/31/2024 | 43 | -45 | -68 | -68 | N/A |
| 9/30/2024 | 18 | -73 | -53 | -53 | N/A |
| 6/30/2024 | 22 | -50 | -36 | -35 | N/A |
| 3/31/2024 | 33 | -44 | -49 | -49 | N/A |
| 12/31/2023 | 32 | -54 | -50 | -49 | N/A |
| 9/30/2023 | 34 | -52 | -50 | -50 | N/A |
| 6/30/2023 | 36 | -53 | -58 | -58 | N/A |
| 3/31/2023 | 29 | -53 | -48 | -48 | N/A |
| 12/31/2022 | 22 | -50 | -58 | -57 | N/A |
| 9/30/2022 | 18 | -40 | -39 | -38 | N/A |
| 6/30/2022 | 19 | -47 | -37 | -36 | N/A |
| 3/31/2022 | 20 | -51 | 4 | 6 | N/A |
| 12/31/2021 | 17 | -53 | 7 | 9 | N/A |
| 9/30/2021 | 15 | -57 | 4 | 5 | N/A |
| 6/30/2021 | 14 | -57 | 2 | 3 | N/A |
| 3/31/2021 | 11 | -49 | -33 | -32 | N/A |
| 12/31/2020 | 7 | -45 | -15 | -15 | N/A |
| 9/30/2020 | 4 | -33 | 0 | 1 | N/A |
| 6/30/2020 | 2 | -28 | 15 | 16 | N/A |
| 3/31/2020 | 1 | -26 | 9 | 9 | N/A |
| 12/31/2019 | 0 | -26 | N/A | 2 | N/A |
| 9/30/2019 | 0 | -23 | N/A | -10 | N/A |
| 6/30/2019 | N/A | -23 | N/A | -23 | N/A |
| 3/31/2019 | N/A | -24 | N/A | -23 | N/A |
| 12/31/2018 | N/A | -23 | N/A | -21 | N/A |
| 9/30/2018 | N/A | -15 | N/A | -20 | N/A |
| 6/30/2018 | N/A | -6 | N/A | -18 | N/A |
| 3/31/2018 | 0 | -4 | N/A | -17 | N/A |
| 12/31/2017 | 0 | -2 | N/A | -13 | N/A |
| 9/30/2017 | 1 | -7 | N/A | -12 | N/A |
| 6/30/2017 | 1 | -12 | N/A | -11 | N/A |
| 3/31/2017 | 1 | -11 | N/A | -12 | N/A |
| 12/31/2016 | 1 | -10 | N/A | -12 | N/A |
| 9/30/2016 | 0 | -10 | N/A | -13 | N/A |
| 6/30/2016 | N/A | -10 | N/A | -12 | N/A |
| 3/31/2016 | N/A | -10 | N/A | -13 | N/A |
| 12/31/2015 | N/A | -10 | N/A | -12 | N/A |
| 9/30/2015 | 0 | -12 | N/A | -13 | N/A |
| 6/30/2015 | 0 | -15 | N/A | -14 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che SLN rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che SLN rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che SLN rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di SLN ( 56.2% all'anno) crescerà più rapidamente del mercato US ( 11.6% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di SLN ( 56.2% all'anno) crescerà più rapidamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che SLN non sarà più redditizia tra 3 anni.
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 23:15 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Silence Therapeutics plc è coperta da 13 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Howard Miller | Canaccord Genuity |
| Keay Nakae | Chardan Capital Markets, LLC |
| Nathaniel Calloway | Edison Investment Research |